Dermatology Enrollment Form



Fax Referral To: 1-877-232-5455

Address: 500 Ala Moana Blvd., Ste 1-A Honolulu, HI 96813

Phone: 1-800-896-1464

SIX	simple Steps to S	Submitting a Referral
PATIENT INFORMATION (Complete o	or include demographi	ic sheet)
Patient Name:		DOB:
Address:		City, State, ZIP Code:
Gender: Male Female		
Preferred Contact Methods: Phone (to prime	nary # provided below	w) 🔲 Text (to cell # provided below) 🔲 Email (to email provided
below)		
		ail, Specialty Pharmacy will attempt to contact by phone.
		Alternate Phone:
If Minor , Parent/Caregiver/Guardian Name (La		
Relationship to minor:		
Email:	Last F	Four of SSN: Primary Language:
_		
2 PRESCRIBER INFORMATION		
Prescriber's Name:		State License #:
NPI #: DEA #: Gre	oup or Hospital:	
Address:	City	y, State, ZIP Code:contact's Phone:
Phone: Fax	Contact Perso	on: Contact's Phone:
DIAGNOSIS AND CLINICAL INFOR Needs by Date:	MATION	on and insurance cards with this form, if available (front and back) Patient Clinical Information: Allergies:
Ship to: Patient Office Other	r:	Weight:lb/kg Height:
		In/cm TB Test Result:
		Date:
<u>Diagnosis (ICD-10):</u>	_	
L40.0 Psoriasis Vulgaris		Nursing:
		Specialty pharmacy to coordinate injection training/home health
Psoriasis		nurse visit as necessary? Yes No
L40.50 Arthropathic Psoriasis, Unspecified		Site of Care: MD office Infusion Clinic Outpatient
Other Psoriatic Arthropathy L40.8 O		Health Home Health
L40.9 Psoriasis, Unspecified	_	Injection training not necessary. Date training occurred:
Hidradenitis Suppur		
Other Code: Description		Reason: MD office training patient Pt already independent Referred by MD to alternate trainer

Dermatology Enrollment Form Medications A-C

(Avsola, Cimzia)

	Please Comp	lete Patient , Prescriber a	and Patient Clinical Information	<u>n</u>
Patient Name: Patient DOB			atient DOB:	
		Prescriber Phone:		
atient Clinical I				
lergies:	lb/kg Heig			5 .
			3 Test Result:	Date:
	TION INFORMATIO			
MEDICATION	STRENGTH	DOSE	& DIRECTIONS	QUANTITY/REFILLS
Avsola	100 mg vial	☐ Induction Dose: Infuse IV at 5 and every 8 weeks thereafter ☐ Maintenance Dose: Infuse IV (Dose =mg) every 8 weeks ☐ Other:_		Quantity: # of 100 mg vial(s) Refills:
☐ Cimzia	Cimzia Starter Kit (6 prefilled syringes)	other week ☐ Patients (with body weight ≤ 9 injections of 200 mg each) initial 200 mg every other week Psoriatic Arthritis Loading Dose:	,	Quantity: 1 Kit Refills: 0
☐ Cimzia	200mg/1 mL prefilled syringe 200mg vial	Psoriasis Maintenance Dose: 400 mg (given as 2 subcutan every other week) 200 mg every other week Psoriatic Arthritis Maintenance D 200 mg every other week 400 mg (given as 2 subcutan every 4 weeks) Other:	Pose:	Quantity: Refills:
Patient is interested	d in patient support programs	STAMP SIGNATURE NOT A	LLOWED Ancillary supplies and kits provide	ed as needed for administration
(ID)	_		TAMP SIGNATURE NOT ALLO	WED)
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute		May Substitute / Product Selection Permitted / Substitution Permissible		
Prescriber's Signature:Date:		Prescriber's Signature:	Date:	

Dermatology Enrollment Form Medications C-G

(Cosentyx, Enbrel)

Prescriber's S	ignature:	Date:	Prescriber's Signature:	Date:
DAW / May Not Sub	ostitute	Do Not Substitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible	Data
	6PRESCRIBER SIG	GNATURE REQUIRED (S	FAMP SIGNATURE NOT ALLO	WED)
Patient is interested	d in patient support programs	STAMP SIGNATURE NOT A	Ancillary supplies and kits provide	ed as needed for administration
Enbrel	for use with the AutoTouch reusable autoinjector only (Prescriber MUST supply). CVS does not order the autoinjector. 25 mg/0.5 mL prefilled syringe 25 mg/0.5 mL solution in a single-dose vial	days apart) for 3 months, then Psoriasis Maintenance Dos	nject 50 mg SC TWICE a week (3 to 4 maintenance dosing. e: Inject 50 mg SC ONCE a week. ect 50 mg SC ONCE a week.	Refills:
	50 mg/mL Sureclick Autoinjector 50 mg/mL prefilled syringe 50 mg/mL Enbrel Mini prefilled cartridge			Quantity:
☐ Cosentyx 50 mg wt ≥ 50 kg)	Sensoready Pen (1x150 mg/mL) Prefilled Syringe (1x150 mg/mL)	Pediatric: Loading Dose: Inject 150 m	g subcutaneously on Weeks 0, 1, 2, 3 50 mg subcutaneously on Week 4,	Quantity: Refills:
Cosentyx '5 mg wt ≥ 15 kg und < 50 kg)	Prefilled Syringe (1x75 mg/0.5 mL)		subcutaneously on Weeks 0, 1, 2, 3 5 mg subcutaneously on Week 4, then	Quantity: Refills:
Cosentyx 00 mg	Sensoready Pen (2x150 mg/mL) Prefilled Syringe (2x150 mg/mL)		ng subcutaneously on Weeks 0, 1, 2, 3 800 mg subcutaneously on Week 4,	Quantity: Refills:
Cosentyx 50 mg	Sensoready Pen (1x150 mg/mL) Prefilled Syringe (1x150 mg/mL)		g subcutaneously on Weeks 0, 1, 2, 3 50 mg subcutaneously on Week 4,	Quantity: Refills:
MEDICATION			& DIRECTIONS	QUANTITY/REFILLS
	TION INFORMATION		B Test Result:	Date:
ergies:	lb/kg Height			ъ.
tient Clinical I		·	rescriber Phone:	
Patient Name: F Prescriber Name: F				

Dermatology Enrollment Form Medications H

(Humira)

atient Name:	-	F	Patient DOB:	
rescriber Name:			Prescriber Phone:	
<u>atient Clinical Ir</u>				
lergies:	lb/kg Height:			
		In/cm T	B Test Result:	Date:
	TION INFORMATION			
MEDICATION	STRENGTH	DOS	E & DIRECTIONS	QUANTITY/REFILLS
	Psoriasis 40 mg/0.4 mL Starter Package Citrate			
Humira	Free Psoriasis 80 mg/0.8 mL and 40 mg/0.4 mL Starter	Psoriasis Induction Dose 40 mg SC on day 8, then 40	e: 80 mg SC initial dose, followed by mg every other week.	Quantity: 1 package Refills: 0
	Package Citrate Free	D	200	
Humira	☐ 40 mg/0.4 mL Pen Citrate Free ☐ 40 mg/0.4 prefilled syringe Citrate Free	every other week. Psoriatic Arthritis Dose: other week.	Oose: Inject one 40 mg pen/syringe SC Inject one 40 mg pen/syringe SC every	Quantity:
		Other:		
☐ Humira	30 kg (66 lbs) to less than 60 kg (132 lbs); ≥ 12 years: ☐ Adolescent Hidradenitis Suppurativa 80 mg/0.8 mL and 40 mg/0.4 mL Starter Package Citrate Free	subsequent doses	opurativa Initial Dose: en 40mg every other week on day 8 and	Quantity: 1 kit (3 Pens) Refills: 0
☐ Humira	60 kg (132 lbs) and greater; ≥ 12 years: Adult Hidradenitis Suppurativa 80 mg/0.8 mL Starter Package Citrate Free	Hidradenitis Suppurativa Ini Inject SC 160mg Day 1, tl 40mg every week (Day 29) Inject SC 80mg Day 1, 80 (Day 15), then 40mg every v Inject SC 160mg Day 1, tl 80mg every other week (Da Inject SC 80mg Day 1, 80 (Day 15), then 80mg every cl doses Other:	Quantity: 1 kit (3 Pens) Refills: 0	
☐ Humira	30 kg (66 lbs) to less than 60 kg (132 lbs); ≥ 12 years:	Adolescent Hidradenitis Suppurativa Maintenance Dose: Inject SC 40mg every other week Other:		Quantity: Refills:
] Humira	60 kg (132 lbs) and greater; ≥ 12 years: 40 mg/0.4 mL Pen Citrate Free 40 mg/0.4 prefilled syringe Citrate Free 80 mg/0.8 mL Pen Citrate Free	Hidradenitis Suppurativa Maintenance Dose: Inject SC 40mg every week Inject SC 80 mg every other week		Quantity: Refills:
Patient is interested i	in patient support programs	STAMP SIGNATURE NOT	ALLOWED Ancillary supplies and kits provi	ded as needed for administration
	6 PRESCRIBER SIGNA	ATURE REQUIRED (S	TAMP SIGNATURE NOT ALLO	WED)
"Dispense As Writte DAW / May Not Subs	n" / Brand Medically Necessary / Do N stitute	ot Substitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible	
	Prescriber's Signature:Date:		Prescriber's Signature:	Date:

Dermatology Enrollment Form Medications I-S

(Ilumya, Inflectra, Infliximab, Orencia, Otezla, Remicade, Renflexis, Rinvoq, Siliq, Simponi, Simponi ARIA)

Prescriber Name:				and Patient Clinical Information		
Patient Clinical Information: Ilb/kg Height:in/cm T8 Test Result: Date:				Patient DOB:		
Date:			P	rescriber Phone:		
Date:	Allergies:					
DOSE-& DIRECTIONS	Weight:	lb/kg He	ight:In/cm T	B Test Result:	Date:	
DOSE-& DIRECTIONS	PRESCRIPT	ION INFORMAT	ION			
Sepriasis Induction Dose: Inject one pre-filled syringe (100 mg) SC at weeks 0 and 4, then maintenance dosing. Psoriasis Maintenance Dose: Inject one pre-filled syringe (100 mg) SC weeks 0 and 4, then maintenance Dose: Inject one pre-filled syringe (100 mg) SC weeks 0 and 4, then maintenance Dose: Infect one pre-filled syringe (100 mg) SC weeks 0 and 4, then maintenance Dose: Infect one pre-filled syringe (100 mg) SC weeks 0 and 4, then maintenance Dose: Infect one pre-filled syringe (100 mg) SC weeks 0 and 4, then maintenance Dose: Infect one pre-filled syringe (100 mg) SC weeks 0 and 4, then maintenance Dose: Infect one pre-filled syringe (100 mg) SC weeks 0 and 4, then maintenance Dose: Infect one pre-filled syringe (100 mg) SC weeks 0 and 4, then maintenance Dose: Infect one pre-filled syringe (100 mg) SC weeks 0 and 4, then maintenance Dose: Infect one pre-filled syringe (100 mg) SC weeks thereafter 0 mg PO in the morning and 20 mg PO in the morning and 10 mg PO in the evening. Day 1: 10 mg PO in the morning and 20 mg PO in the evening. Day 4: 20 mg PO in the morning and 20 mg PO in the evening. Day 5: 20 mg PO in the morning and 20 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 5: 20 mg PO in the m				DIRECTIONS	QUANTITY/REFILLS	
Inflectra	□ Ilumya		weeks 0 and 4, then maintenance Psoriasis Maintenance Dose: I every 12 weeks.	e dosing.	Quantity: Refills:	
Otezla		100 mg vial	Induction Dose: Infuse IV at 5 and every 8 weeks thereafter Maintenance Dose: Infuse IV a		Quantity: # of 100 mg vial(s) Refills:	
Otezla	Orencia		Inject 125 mg SC once weekly		Quantity:	
Otezla 30 mg tablet	Otezla		PO in the evening. Day 3: 10 mg PO in the morning a Day 4: 20 mg PO in the morning a Day 5: 20 mg PO in the morning a	nd 20 mg PO in the evening. and 20 mg PO in the evening. and 30 mg PO in the evening.	Quantity: 1 pack Refills: 0	
and every 8 weeks thereafter Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks # of 100 mg via Refills: Rinvoq	Otezla	30 mg tablet		olet PO twice daily.	Quantity: Refills:	
Take one 15 mg tablet PO daily Carton of two 210 mg/1.5 mL single-dose prefilled syringes Inject one prefilled syringe (210 mg) SC at weeks 0, 1 and 2, followed by one prefilled syringe (210 mg) every 2 weeks. Prescribers must be certified in the SILIQ REMS Program to prescribe SILIQ. Please visit the following REMS website to register before prescribing SILIQ: SILIQ REMS Website (https://siliqrems.com/SiliqUI/home.u) Simponi		100 mg vial	and every 8 weeks thereafter Maintenance Dose: Infuse IV a		Quantity: # of 100 mg vial(s) Refills:	
Carton of two 210 mg/1.5 mL single-dose prefilled syringes Carton of two 210 mg/1.5 mL single-dose prefilled syringes Carton of two 210 mg/1.5 mL single-dose prefilled syringes Carton of two 210 mg/1.5 mL single-dose prefilled syringes Carton of two 210 mg/1.5 mL single-dose prefilled syringes Carton of two 210 mg/1.5 mL single-dose prefilled syringes Carton of two one prefilled syringe Carton one prefill	Rinvoq	15 mg	Take one 15 mg tablet PO daily		Quantity: Refills:	
Simponi ARIA Single-dose vial Patient is interested in patient support programs STAMP SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED) "Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitutio / "Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitutio / May Substitute / Product Selection Permitted /	Siliq	210 mg/1.5 mL single-dose	one prefilled syringe (210 mg) ever in the SILIQ REMS Program to pre REMS website to register before p	ery 2 weeks. Prescribers must be certified escribe SILIQ. Please visit the following prescribing SILIQ: SILIQ REMS Website	Quantity: Refills:	
Psoriatic Arthritis Dosing: Simponi	Simponi	SmartJect Autoinjector 50 mg/0.5 mL	Psoriatic Arthritis Dose: Inject			
*Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / May Substitute / Product Selection Permitted /		50 mg/4 mL in a	Induction Dose: 2 mg/kg IV infusi then every 8 weeks thereafter	Quantity: # of 50 mg vial Refills:		
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / May Substitute / Product Selection Permitted /	Patient is interested	_		, , , ,		
DAM / M. Mar O Barton	•	n" / Brand Medically Necess		May Substitute / Product Selection Permitted /	-	
	DAW / May Not Substitute Prescriber's Signature: Date:			Date:		

Dermatology Enrollment Form Medications S-Z

(Skyrizi, Stelara, Taltz, Tremfya, Xeljanz)

	Please Complete	e Patient , Prescriber a	and Patient Clinical Information	
Patient Name:				
Prescriber Name: _		Pr	rescriber Phone:	
<u>Patient Clinical Inf</u>				
Allergies: Weight:	lh/ka Height:	In/cm Ti	B Test Result:	Date:
	ON INFORMATION		D rest result.	Date
MEDICATION	STRENGTH	DOSE	& DIRECTIONS	QUANTITY/REFILLS
Skyrizi	☐ 150 mg/mL single-dose Pen ☐ 150 mg/mL single-dose prefilled syringe	Psoriasis Induction Dose: maintenance dosing. Psoriasis Maintenance Do Other:	Inject 150 mg SC at Weeks 0 and 4, then ose: Inject 150mg SC every 12 weeks.	Quantity: Refills:
Stelara	45 mg/0.5 mL prefilled syringe 90 mg/mL prefilled syringe	and 4 weeks later, followed	00 kg (220 lbs): Inject 90 mg SC initially	Quantity: Refills:
☐ Taltz	80 mg Single Dose Autoinjector 80 mg Single Dose prefilled syringe	first induction dose 2 weeks Induction Dose: Inject SC (weeks 2-10). Final Induction Dose: Inject Maintenance Dose: Inject Pediatric Psoriasis Dosing: For patients weighing less th 40 mg at Week 0, follower For patients weighing 25-50 80 mg at Week 0, follower For patients weighing greater	cone 80 mg injection every 2 weeks ect SC one 80 mg injection (week 12). et SC one 80 mg injection every 4 weeks. ean 25 kg dose: ed by 20 mg every 4 weeks. ed by 40 mg every 4 weeks.	Quantity: 3 Pens/Syringes 2 Pens/Syringes 1 Pens/Syringes Refills:
☐ Taltz	☐ 80 mg Single Dose Autoinjector ☐ 80 mg Single Dose prefilled syringe	Psoriatic Arthritis Dosing: Starting Dose: Inject SC two 80 mg injections on Day 1. Maintenance Dose: Inject SC one 80 mg injection every 4 weeks.		Quantity: Refills:
☐ Tremfya	☐ 100 mg/mL prefilled syringe ☐ 100 mg/mL One- Press patient- controlled injector	Starting Dose: Inject 100 mg SC at weeks 0 and 4, then maintenance dosing Maintenance Dose: Inject 100 mg SC every 8 weeks		Quantity: Refills:
Xeljanz	5 mg Tablet 11 mg XR Tablet	Take one 5 mg tablet PO twice daily Take one 11 mg PO once daily Other:		Quantity: Refills:
_	n patient support programs PRESCRIBER SIGN	STAMP SIGNATURE NOT A	Ancillary supplies and kits provi	ded as needed for administration
DAW / May Not Substi	nature:		May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: ATTN: New York and Iowa providers, p	Date:

Dermatology Enrollment Form Nursing Medications

Ple	ease Complete	e Patient , Prescriber	and Patient Clinical Information	<u>1</u>		
Patient Name:		P	atient DOB:			
Prescriber Name:		P	rescriber Phone:			
Patient Clinical Information						
Allergies:			B Test Result:			
		In/cm T	B Test Result:	Date:		
5 PRESCRIPTION IN	FORMATION					
Complete Items below, r	equired for Home	a Infusion/Coram AIS:				
MEDICATION/SUPPLIES	ROUTE		RENGTH/DIRECTIONS	OUANTITY/REFILLS		
Catheter PIV PORT PICC	IV	Catheter Care/Flush – On to maintain IV access and PIV – NS 5 mL (Heparin 10	ly on drug admin days – SASH or PRN patency units/mL 3-5 mL if multiple days) Heparin 100 units/mL 3-5mL, and/or	Quantity: Refills:		
Epinephrine **nursing requires**	□ IM □ SC	Peds 1:2000, 0.3 mL (1! Infant 0.1mL/0.1 mL, 0. PRN severe allergic reactions	☐ Adult 1:1000, 0.3 mL (>30 kg/>66 lbs) ☐ Peds 1:2000, 0.3 mL (15-30 kg/33-66 lbs) ☐ Infant 0.1mL/0.1 mL, 0.1 mL (7.5-15 kg/16.5-33 lbs) PRN severe allergic reaction – Call 911 May repeat in 5-15 minutes as needed			
Premed Antihistamine: Diphenhydramine Other: Other:			Dose will be rounded to the nearest vial size			
☐ Flush Orders	Peripheral Access Central Venus Access	0.9% Sodium Chloride after medication and IVP f Heparin units perflush and as directed	Send quantity sufficient for medication days supply			
Patient is interested in patient sup	oport programs	STAMP SIGNATURE NOT A	LLOWED Ancillary supplies and kits pro	vided as needed for administration		
6 PRE	SCRIBER SIGN	NATURE REQUIRED (S	TAMP SIGNATURE NOT ALLOW	/ED)		
DAW / May Not Substitute		Not Substitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible			
Prescriber's Signature:		Date:	Prescriber's Signature:	Date:		
CA MA NC & DD: Interchange is	mandated unless Prescribe	er writes the words "No Substitution"	ATTN: New York and Iowa providers,	nlease submit electronic prescription		
- i, in it is it. interesting is			ATTIMON TORKAILATONA PIOVILLOIS	, please sabiliti dicott offic proscription		

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2022 CVS Specialty and one of its affiliates. 75-35829E 03/18/22